drugset / Trial / NCT00223899
A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety of intratumorally injected VCL-IM01 at doses of 0.5 mg (1 tumor), 1.5 mg (1 tumor), 5 mg (1 tumor), 10 mg (2 tumors, 5 mg per tumor) and 15 mg (3 tumors, 5 mg per tumor) followed by electroporation.
Timeline
- Start
- 2005-07
- Primary completion
- 2008-06
- Completion
- 2008-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VCL-IM01 | Other / unclassified | 0.5 mg | Other |
| Subject | VCL-IM01 | Other / unclassified | 1.5 mg | Other |
| Subject | VCL-IM01 | Other / unclassified | 5 mg | Other |
| Subject | VCL-IM01 | Other / unclassified | 10 mg | Other |
| Subject | VCL-IM01 | Other / unclassified | 15 mg | Other |